NEW YORK, Nov. 28—Japanese pharmaceutical giant Takeda said Wednesday that it would build a 27,000 square meter research facility dedicated to genomics-based drug discovery research. The center, to be built at the company's Osaka plant, is scheduled to be finished in February 2005.
Takeda will dedicate the research center to early-stage drug screening and development, compound library expansion, and pharmacokinetics research. Drug development at the Osaka facility will follow from discovery research conducted on disease specific genes at the company's pharmaceutical research division in Tsukuba Science City. Takeda estimates the center will cost $17 billion yen ($140 million) to develop.
Takeda, a Japanese drug and vitamin powerhouse with annual sales topping $7 billion, has recently made other significant investments in genomics research. Earlier this month, the company announced plans for a 4,5000 square meter research center dedicated to gene and protein function analysis. In October, the company launched a $100 million biotech investment fund based out of Palo Alto, Calif.
Takeda is also part of the international consortium of pharmaceutical companies that have access to findings from Human Genome Sciences, and in March 2000 signed a 5-year multi-database subscription with Celera.